NTRP - ニュ―ロトロ―プ (Neurotrope Inc.) ニュ―ロトロ―プ

 NTRPのチャート


 NTRPの企業情報

symbol NTRP
会社名 Neurotrope Inc (ニュ―ロトロ―プ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 ソフトウェア   医療関連(Health Care)
概要 事業概要 Neurotrope Inc. formerly BlueFlash Communications Inc. is a biopharmaceutical company with its product candidates in pre-clinical and clinical development. The Company is focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease (AD) which is in the clinical testing stage. Bryostatin which is a protein kinase C (PKC) Alpha and e activator is also developed for other neurodegenerative or cognitive diseases and dysfunctions which are in pre-clinical testing. Its second generation PKC activators such as the Bryologs are meant for the treatment of central nervous system disorders lysosomal storage diseases stroke cardio protection and traumatic brain injury. It develops Bryostatin-1 for the treatment of Alzheimer's disease along with the rare (Orphan) diseases such as Fragile X Syndrome and Niemann-Pick Type C. It has completed Phase IIa clinical trials of Bryostatin-1 for the treatment of patients with AD.   ニュ―ロトロ―プは米国のバイオ医薬品メ―カ―。神経及び精神の障害や疾患の治療薬の開発に注力する。主な開発パイプラインには、アルツハイマ―病、希少疾病、脆弱X染色体症候群、ニ―マン・ピック病C型を治療対象とする「Bryostain 1」がある。本社はニューヨーク。   
本社所在地 205 East 42nd Street 17th Floor New York NY 10017 USA
代表者氏名 Joshua N. Silverman ジョシュア・N・シルバーマン
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 973-242-0005
設立年月日 40544
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 5人
url www.neurotropebioscience.com
nasdaq_url https://www.nasdaq.com/symbol/ntrp
adr_tso
EBITDA EBITDA(百万ドル) -10.81172
終値(lastsale) 7.5805
時価総額(marketcap) 59959427.7865
時価総額 時価総額(百万ドル) 54.73508
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 42.91518
当期純利益 当期純利益(百万ドル) -10.71814
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Neurotrope Inc revenues was not reported. Net loss decreased 32% to $4.1M. Lower net loss reflects Research and development decrease of 73% to $776K (expense) General and administrative decrease of 20% to $2.1M (expense) Loss on abandonment of fixed assets decrease from $34K (expense) to $0K. Basic Earnings per Share excluding Extraordinary Items increased from -$0.81 to -$0.52.

 NTRPのテクニカル分析


 NTRPのニュース

   Insider Buying: Neurotrope Inc (NASDAQ:NTRP) Director Acquires $53,500.00 in Stock  2020/10/22 05:08:50 Stock Observer
Neurotrope Inc (NASDAQ:NTRP) Director Joshua Silverman bought 50,000 shares of Neurotrope stock in a transaction dated Thursday, October 15th. The shares were bought at an average cost of $1.07 per share, with a total value of $53,500.00. Following the completion of the acquisition, the director now owns 50,000 shares of the company’s stock, valued at […]
   Neurotrope Inc (NASDAQ:NTRP) Director Acquires $53,500.00 in Stock  2020/10/21 08:38:42 Dakota Financial News
Neurotrope Inc (NASDAQ:NTRP) Director Joshua Silverman bought 50,000 shares of the stock in a transaction dated Thursday, October 15th. The stock was purchased at an average cost of $1.07 per share, with a total value of $53,500.00. Following the completion of the purchase, the director now directly owns 50,000 shares in the company, valued at […]
   BryoLogyx Announces Agreements with Neurotrope to Acquire Bryostatin-1 Immuno-Oncology Data Package, Supply Synthetic Bryostatin-1  2020/06/10 12:00:00 Business Wire
DANVILLE, Calif.--(BUSINESS WIRE)--BryoLogyx announces agreements with Neurotrope to acquire bryostatin-1 immuno-oncology data package and supply synthetic bryostatin-1
   Neurotrope : Launches New Long-Term Clinical Trial of Bryostatin with the National Institutes of Health for the Treatment of Patients with Alzheimer's Disease | MarketScreener  2020/05/28 13:56:12 MarketScreener
- New Phase 2 Study to Be Conducted in Collaboration with NIHUnder a $2.7 Million Grant- -Management to Host Investor Conference Call and Webcast Today at 11:00… | May 28, 2020
   Neurotrope Rips 150% Higher On Improved Alzheimer's Data, NIH Funding  2020/01/22 16:14:15 Benzinga
Shares of thinly-traded microcap biopharma Neurotrope Inc (NASDAQ: NTRP ) gap-opened sharply higher on above 50 times average volume following a corporate update from the company. Detailed Analysis Shows Promise Following the completion of data analysis for a confirmatory Phase 2 study dubbed "203 study" that evaluated its experimental Alzheimer's disease candidate Bryostatin-1 , Neurotrope said the data showed improvement in cognitive function of pre-specified Moderate Stratum patients at week 13, which is the primary endpoint. "The data suggests that Bryostatin may still be considered a new approach to Alzheimer's treatment," said Dr. Marwan Sabbagh, who helped design the trial … Full story available on Benzinga.com
   Insider Buying: Neurotrope Inc (NASDAQ:NTRP) Director Acquires $53,500.00 in Stock  2020/10/22 05:08:50 Stock Observer
Neurotrope Inc (NASDAQ:NTRP) Director Joshua Silverman bought 50,000 shares of Neurotrope stock in a transaction dated Thursday, October 15th. The shares were bought at an average cost of $1.07 per share, with a total value of $53,500.00. Following the completion of the acquisition, the director now owns 50,000 shares of the company’s stock, valued at […]
   Neurotrope Inc (NASDAQ:NTRP) Director Acquires $53,500.00 in Stock  2020/10/21 08:38:42 Dakota Financial News
Neurotrope Inc (NASDAQ:NTRP) Director Joshua Silverman bought 50,000 shares of the stock in a transaction dated Thursday, October 15th. The stock was purchased at an average cost of $1.07 per share, with a total value of $53,500.00. Following the completion of the purchase, the director now directly owns 50,000 shares in the company, valued at […]
   BryoLogyx Announces Agreements with Neurotrope to Acquire Bryostatin-1 Immuno-Oncology Data Package, Supply Synthetic Bryostatin-1  2020/06/10 12:00:00 Business Wire
DANVILLE, Calif.--(BUSINESS WIRE)--BryoLogyx announces agreements with Neurotrope to acquire bryostatin-1 immuno-oncology data package and supply synthetic bryostatin-1
   Neurotrope : Launches New Long-Term Clinical Trial of Bryostatin with the National Institutes of Health for the Treatment of Patients with Alzheimer's Disease | MarketScreener  2020/05/28 13:56:12 MarketScreener
- New Phase 2 Study to Be Conducted in Collaboration with NIHUnder a $2.7 Million Grant- -Management to Host Investor Conference Call and Webcast Today at 11:00… | May 28, 2020
   Neurotrope Rips 150% Higher On Improved Alzheimer's Data, NIH Funding  2020/01/22 16:14:15 Benzinga
Shares of thinly-traded microcap biopharma Neurotrope Inc (NASDAQ: NTRP ) gap-opened sharply higher on above 50 times average volume following a corporate update from the company. Detailed Analysis Shows Promise Following the completion of data analysis for a confirmatory Phase 2 study dubbed "203 study" that evaluated its experimental Alzheimer's disease candidate Bryostatin-1 , Neurotrope said the data showed improvement in cognitive function of pre-specified Moderate Stratum patients at week 13, which is the primary endpoint. "The data suggests that Bryostatin may still be considered a new approach to Alzheimer's treatment," said Dr. Marwan Sabbagh, who helped design the trial … Full story available on Benzinga.com

 関連キーワード  (IT 米国株 ニュ―ロトロ―プ NTRP Neurotrope Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)